Sugi Predict

Sugi Predict / Compounds / SCHEMBL14788170

SCHEMBL14788170

SCHEMBL14788170

COc1cc(NCCO[Si](C)(C)C(C)(C)C)cc(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PRKACA P17612 1/20 0.38
▸ PRKACG P22612 1/20 0.38
▸ PRKACB P22694 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ F2 P00734 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ DHFR P00374 2/20 0.34
▸ MTNR1A P48039 1/20 0.33
▸ MTNR1B P49286 1/20 0.33
▸ CNR1 P21554 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18739778 0.81 IDO1 (0.32) —
SCHEMBL1969773 0.78 IDO1 (0.39) MAPTALDH1A1
SCHEMBL12208099 0.77 DUT (0.30) —
SCHEMBL28572444 0.76 GAA (0.47) PRKACAPRKACGPRKACBGAAMAPT
SCHEMBL2599179 0.76 MAPT (0.44) MAPTF2ALDH1A1
SCHEMBL5882318 0.75 ALDH1A1 (0.41) ALDH1A1
SCHEMBL21425529 0.74 DHFR (0.37) DHFR
SCHEMBL1023793 0.73 APP (0.37) GAAMAPT
SCHEMBL2523541 0.73 ALDH1A1 (0.41) GAAMAPTKMT2APOLBALDH1A1
SCHEMBL15919355 0.73 MAPT (0.34) GAAMAPTF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350298-A Preparation method of erdasatinib and intermediate compound used for method 沈阳药科大学 2025-01-24 — — CN disclosed
US-20240002365-A1 PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS BETA PHARMA, INC. 2024-01-04 — — US disclosed
CN-114945367-A Pyridazine and 1,2, 4-triazine derivatives as FGFR kinase inhibitors 贝达医药公司 2022-08-26 — — CN disclosed
US-20220135544-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2022-05-05 — — US disclosed
WO-2021146163-A1 PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS BETA PHARMA, INC. (US) 2021-07-22 — — WO disclosed
US-20200131153-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2020-04-30 — — US disclosed
US-20180127397-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2018-05-10 — — US disclosed
US-20180127397-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2018-05-10 — — US disclosed
US-9850228-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2017-12-26 — — US disclosed
US-9850228-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2017-12-26 — — US disclosed
US-20160311800-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2016-10-27 — — US disclosed
US-20160311800-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2016-10-27 — — US disclosed
US-9464071-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-10-11 — — US disclosed
US-9464071-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2016-10-11 — — US disclosed
US-20150105368-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-04-16 — — US disclosed
US-20150105368-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2015-04-16 — — US disclosed
US-8895601-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2014-11-25 — — US disclosed
US-8895601-B2 Pyrazolyl quinoxaline kinase inhibitors ASTEX THERAPEUTICS LTD (GB) 2014-11-25 — — US disclosed
US-20130072457-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2013-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131153-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS PDXK, DCK, PDPK1 PRKACA 222/4885PRKACG 211/4885PRKACB 256/4885
US-20130072457-A1 PYRAZOLYL QUINAZOLINE KINASE INHIBITORS MAP3K5, MAP3K1, MAP4K2 PRKACA 190/4885PRKACG 198/4885PRKACB 226/4885
US-20150105368-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS PDXK, DCK, PDPK1 PRKACA 222/4885PRKACG 211/4885PRKACB 256/4885
US-20180127397-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS PDXK, DCK, PDPK1 PRKACA 222/4885PRKACG 211/4885PRKACB 256/4885
US-20220135544-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS PDXK, DCK, PDPK1 PRKACA 222/4885PRKACG 211/4885PRKACB 256/4885
US-20240002365-A1 PYRIDAZINE AND 1,2,4-TRIAZINE DERIVATIVES AS FGFR KINASE INHIBITORS FGFR1, FGFR2, FGFR4 PRKACA 2617/4885PRKACG 3078/4885PRKACB 3033/4885
US-20160311800-A1 PYRAZOLYL QUINOXALINE KINASE INHIBITORS PDXK, DCK, PDPK1 PRKACA 222/4885PRKACG 211/4885PRKACB 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.